Needham & Company Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Following Positive Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DGNX

Go back to Needham & Company Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Following Positive Data

Rhythm Pharmaceuticals (RYTM) Phase 3 Clinical Trials of Setmelanotide Met Primary and Secondary Endpoints

August 7, 2019 7:09 AM EDT

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced positive topline results from two pivotal, Phase 3 clinical trials evaluating setmelanotide, the companys melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities. Both studies met their primary endpoints and all key secondary endpoints, demonstrating a statistically... More